Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H19N3.C4H4O4 |
Molecular Weight | 381.425 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.[H][C@]12CN(C)CCN1C3=C(CC4=C2C=CC=C4)C=CC=N3
InChI
InChIKey=RPUBHMMISKEXSR-MLCLTIQSSA-N
InChI=1S/C17H19N3.C4H4O4/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20;5-3(6)1-2-4(7)8/h2-8,16H,9-12H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t16-;/m1./s1
Esmirtazapine (S-(+)mirtazapine or ORG-50081) is an enantiomer of mirtazapine (REMERON®), a high-affinity antagonist at 5-HT2/5-HT3 and H1 receptors, used in the treatment of depression. Esmirtazapine has a shorter plasma half-life than the R(−) enantiomer. Esmirtazapine is preferentially metabolized into an 8-hydroxy glucuronide. Organon was developing esmirtazapine for the treatment of hot flushes (vasomotor symptoms) associated with the menopause and insomnia.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Pathophysiology of depression and mechanisms of treatment. | 2002 Mar |
|
Hypertensive urgency with clonidine and mirtazepine. | 2004 Sep-Oct |
|
The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. | 2005 |
|
Mirtazepine for MDMA-induced depression. | 2005 May-Jun |
|
Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient. | 2005 Nov-Dec |
|
Chiral resolution and binding study of 1,3,4,14b-tetrahydro-2,10-dimethyl-2H,10H-pyrazino[2,1-d]pyrrolo[1,2-b] [1,2,5]benzotriazepine (10-methyl-10-azaaptazepine) and 2-methyl-1,3,4,14b-tetrahydro-2H-pyrazino[2,1-d]pyrrolo[1,2-b] [1,2,5]benzothiadiazepine 10,10-dioxide (tiaaptazepine). | 2005 Nov-Dec |
|
[Distribution effects of orthographic similarity and priming by masked repetition]. | 2005 Sep |
|
[Compliance in psychiatry: results of a survey of depressed patients using orally disintegrating tablet]. | 2006 |
|
Family history, early adversity and the hypothalamic-pituitary-adrenal (HPA) axis: Mediation of the vulnerability to mood disorders. | 2007 |
|
[Differentiated approach to the therapy of endogenous anxious depression]. | 2007 |
|
[Depressive disturbances during antiviral therapy in patients with type C hepatitis]. | 2007 |
|
Post-traumatic stress disorder. | 2007 Aug 1 |
|
A new paradigm for the prediction of antidepressant treatment response. | 2009 |
|
Brain-derived neurotrophic factor: role in depression and suicide. | 2009 |
|
Early presentation following overdose of modified-release paracetamol (Panadol Osteo) with biphasic and prolonged paracetamol absorption. | 2009 Aug 7 |
|
Undertreatment of menopausal symptoms and novel options for comprehensive management. | 2009 Nov |
|
Extreme thermal sensitivity and pain-induced sensitization in a fibromyalgia patient. | 2010 |
|
3D-QSAR design of new escitalopram derivatives for the treatment of major depressive disorders. | 2010 Apr-Jun |
|
Behavioral and developmental changes in rats with prenatal exposure of mirtazapine. | 2010 Jul-Sep |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29756
Created by
admin on Fri Dec 15 15:45:52 GMT 2023 , Edited by admin on Fri Dec 15 15:45:52 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DBSALT001294
Created by
admin on Fri Dec 15 15:45:52 GMT 2023 , Edited by admin on Fri Dec 15 15:45:52 GMT 2023
|
PRIMARY | |||
|
6451144
Created by
admin on Fri Dec 15 15:45:52 GMT 2023 , Edited by admin on Fri Dec 15 15:45:52 GMT 2023
|
PRIMARY | |||
|
CHEMBL1366933
Created by
admin on Fri Dec 15 15:45:52 GMT 2023 , Edited by admin on Fri Dec 15 15:45:52 GMT 2023
|
PRIMARY | |||
|
RR-49
Created by
admin on Fri Dec 15 15:45:52 GMT 2023 , Edited by admin on Fri Dec 15 15:45:52 GMT 2023
|
PRIMARY | |||
|
680993-85-5
Created by
admin on Fri Dec 15 15:45:52 GMT 2023 , Edited by admin on Fri Dec 15 15:45:52 GMT 2023
|
PRIMARY | |||
|
C76940
Created by
admin on Fri Dec 15 15:45:52 GMT 2023 , Edited by admin on Fri Dec 15 15:45:52 GMT 2023
|
PRIMARY | |||
|
100000174954
Created by
admin on Fri Dec 15 15:45:52 GMT 2023 , Edited by admin on Fri Dec 15 15:45:52 GMT 2023
|
PRIMARY | |||
|
I2U18E6JKA
Created by
admin on Fri Dec 15 15:45:52 GMT 2023 , Edited by admin on Fri Dec 15 15:45:52 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD